**Table S1. All data extracted and coded from the included citing papers**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Citing paper** | **Type** | **Modest/****small ES** | **Caution** | **Pointa**  | **Point** **(other)b** | **Cond** | **Disease** | **Treat category** | **Treat type** | **COI** | **Industryfund** | **Funder** |
| Waszczuk *et al.* (2017) | Exp | Y | N | Moderate ES | - | Psych | PTSD | Psy | CBT trauma +Smoking cessation | NR | N | NIH |
| Chan *et al.* (2017) | Exp | N | N | Large ES | - | Psych | ADHD | Drug | MPH | N | N | RGC |
| Leucht and Davis (2017) | N-exp | Y | N | Psych=Gen |  | Psych | Psychosis | Drug | Cariprazine | Y | N | - |
| Cuijpers *et al.* (2017) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Psy | CBASP | N | N | - |
| Jakobsen *et al.* (2017) | Exp | N | N | Small ES | - | Psych | Affective | Drug | SSRIs | N | N | CCIR |
| Cortese *et al.* (2017) | N-exp | N | N | Large ES | - | Psych | ADHD | Drug | MPH | Y | N | - |
| Haddad (2012) | N-exp | N | N | Psych=Gen | - | Psych | All | Drug | All | Y | N | - |
| Mann *et al.* (2016) | Exp | Y | N | Psych=Gen | - | Psych | Addiction | Drug | Nalmefene | Y | Y | Lundbeck |
| Banaschewski *et al.* (2016) | N-exp | N | N | Large ES | - | Psych | ADHD | Drug | MPH | Y | N | - |
| Biagianti *et al.* (2016) | Exp | N | N | Other | 1) | Psych | Psychosis | Psy | Cognitive training | Y | Y | Posit Science |
| Fabbri *et al.* (2016) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | N | Y |  |
| Cuijpers (2016) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Psy | All | N | N | - |
| Moritz *et al.* (2016a) | Exp | N | N | Moderate ES | - | Psych | Psychosis | Drug | Antipsych | N | N | - |
| Lehr *et al.* (2016) | Exp | N | N | Large ES | - | Psych | All | Psy | Internet therapy | Y | N | - |
| Sinclair *et al.* (2016) | Exp | Y | N | Psych=Gen | - | Psych | Addiction | Drug | All | Y | N | - |
| Luderer *et al.* (2016) | N-exp | N | N | Large ES | - | Psych | ADHD | Drug | MPH | Y | N | - |
| Hieronymus *et al.* (2016) | Exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | SSRIs | Y | Y | Lundbeck, GSK, Pfizer, SMRC, B H Found, S Found, SUH, SBF |
| de Vries *et al.* (2016) | Exp | Y | Y | Psych=Gen | - | Psych | Anxiety | Drug | Antidepr | N | N | Dutch Brain Found |
| Nuijten *et al.* (2016) | Exp | Y | N | Psych=Gen | - | Psych | Addiction | Drug | Dexamph | Y | N | NOHRD |
| Davey and Chanen (2016) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | N | N | - |
| Bschor and Kilarski (2016) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | N | N | - |
| Moller-Leimkuhler *et al.* (2016) | N-exp | Y | N | Psych=Gen | - | Psych | All | Drug | All | N | N | - |
| Moritz *et al.* (2016b) | N-exp | N | N | Small ES | - | Psych | Psychosis | Psy | Cognitive training | Y | N | - |
| McIntyre *et al.* (2016) | Exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Vortioxetine | Y | N | Lundbeck |
| Goodwin *et al.* (2016) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | All | Y | N | BAP |
| Frazer (2015) | N-exp | Y | N | Psych=Gen | - | Psych | All | Drug | All | Y | N | - |
| Aubin and Luquiens (2015) | N-exp | N | N | Psych=Gen | - | Psych | Addiction | Drug | Varenicline | Y | N | - |
| Bisson *et al.* (2015) | N-exp | N | N | Small ES | - | Psych | PTSD | Drug | All | N | N | - |
| Leucht *et al.* (2015) | Exp | N | Y | Other | 2) | Both | All | Drug | All | Y | N | - |
| Florea *et al.* (2015) | Exp | Y | N | Relevant small ES | - | Psych | Affective | Drug | Vortioxetine | Y | Y | Lundbeck |
| De Las Cuevas and Penate (2015) | Exp | N | N | Other | 3) | Psych | All | Drug | All | N | N | - |
| Kaufman *et al.* (2015) | N-exp | Y | N | Psych=Gen | - | Psych | Child maltreat | Drug | All | Y | N | - |
| Dold *et al.* (2015) | Exp | N | N | Large ES | - | Psych | Anxiety | Drug | Antipsych | Y | N | - |
| Gotzsche *et al.* (2015) | N-exp | Y | N | Psych=Gen |  | Psych | All | Drug | All | Y | N | - |
| Cleare *et al.* (2015) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | Y | N | BAP |
| Millan *et al.* (2015a) | N-expr | Y | N | Psych=Gen | - | Psych | All | Drug | All | Y | N | - |
| Millan *et al.* (2015b) | N-exp | N | N | Psych=Gen | - | Psych | All | Drug | All | Y | N | - |
| Bhugra *et al.* (2015) | N-exp | Y | N | Psych=Gen | - | Psych | All | Drug | Antipsych | N | N | - |
| Huber and Klug (2015) | N-exp | N | N | Other | 4) | Psych | All | Psy | PDT | N | N | - |
| Lawrie (2015) | N-exp | N | N | Large ES | - | Psych | Psychosis | Drug | Antipsych | Y | N | - |
| Stein (2015) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | N | N | - |
| Kasper and Dold (2015) | N-exp | N | N | Other | 5) | Psych | Affective | Drug | Antidepr | N | N | - |
| Dold and Kasper (2015) | N-exp | N | N | Other | 6) | Psych | Psychosis | Drug | Antipsych | Y | N | - |
| Maia *et al.* (2015) | Exp | N | N | Large ES | - | Psych | ADHD | Drug | MPH | Y | N | - |
| Tajika *et al.* (2015) | Exp | N | N | Moderate ES | - | Psych | All | Drug | All | N | N | - |
| Lally and MacCabe (2015) | N-exp | N | N | Psych=Gen | - | Psych | Psychosis | Drug | Antipsych | N | N | EU-FP7 |
| Liersch-Sumskis *et al.* (2015) | Exp | N | N | Other | 7) | Psych | Psychosis | Drug | Antipsych | N | N | - |
| Sayer *et al.* (2015) | Exp | Y | Y | Relevant small ES |  | Psych | PTSD | Psy | Expressive writing | N | N | VA |
| Kelly (2014) | N-exp | N | N | Psych=Gen | - | Psych | All | Drug | All | N | N |  |
| Aubin *et al.* (2015) | Exp | Y | N | Psych=Gen | - | Psych | Addiction | Drug | Nalmefene | Y | Y | Lundbeck |
| Hoskins *et al.* (2015) | Exp | Y | N | Relevant small ES | - | Psych | PTSD | Drug | All | N | N | WHO |
| Naudet *et al.* (2015) | N-exp | Y | Y | Psych=gen | - | Psych | Affective | Drug | Antidepr | Y | N | - |
| Connolly *et al.* (2015) | N-exp | N | N | Large ES | - | Psych | ADHD | Drug | MPH | N | N | - |
| Bressington and White (2015) | N-exp | Y | N | Psych=Gen | - | Psych | Psychosis | Drug | Antipsych | NR | N | - |
| Jonas *et al.* (2015) | Exp | N | N | Gen=Psych | - | Gen | All | Surgery | All | N | N | US Army Medical Research |
| Hegerl and Mergl (2014) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | Y | Y | Takedal Pharma |
| Veijola *et al.* (2014) | Exp | N | N | Large ES | - | Psych | Psychosis | Drug | Antipsych | Y | N | Acad Finland, MRC, SJ Found, Stanley Found, BBRF NARSAD |
| Tansella *et al.* (2014) | N-exp | N | Y | Psych=Gen | - | Psych | All | Tx | All | N | N | - |
| van den Brink *et al.* (2014) | N-exp | Y | N | Psych=Gen | - | Psych | Addiction | Drug | Nalmefene | Y | N | - |
| Oldham and Ciraulo (2014) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Device | Bright light th | N | N | - |
| Taylor *et al.* (2014) | Exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Aglometine | Y | N | None |
| Mulsant (2014) | N-exp | Y | N | Psych=Gen | - | Psych | All | Drug | All | Y | N | CPA |
| Craddock and Mynors-Wallis (2014) | N-exp | N | N | Psych=Gen | - | Psych | All | Tx | All | N | N | - |
| Hutton and Taylor (2014) | Exp | Y | N | Psych=Gen | - | Psych | Psychosis | Psy | CBT | N | N | - |
| Fountoulakis *et al.* (2014) | N-exp | Y | Y | Psych=Gen | - | Psych | Affective | Drug | Antidepr | Y | N | - |
| DeRubeis *et al.* (2014) | Exp | N | N | Large ES | - | Psych | Affective | Tx | Antidepr; CBT | N | N | NIMH |
| Kelly (2014) | N-exp | N | N | Psych=Gen | - | Psych | All | Drug | All | N | N | - |
| Sommer and Kahn (2014) | N-exp | N | N | Large ES | - | Psych | Psychosis | Drug | Antipsych | N | N | - |
| Correll and Carbon (2014) | N-exp | Y | N | Psych=Gen | - | Psych | All | Tx | All | Y | N | - |
| Maj (2014) | N-exp | Y | N | Psych=Gen | - | Psych | All | Drug | All | NR | N | - |
| Messori *et al.* (2014) | Exp | N | N | Other | 8) | Gen | MI | Surgery | Trombectomy | N | N | - |
| Aleman *et al.* (2014) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Devise | rTMS | N | N | - |
| O'Carroll (2014) | N-exp | Y | N | Psych=Gen | - | Psych | All | Psy | Health psy | N | N | - |
| Nutt *et al.* (2014) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | Y | N | - |
| Adli and Hegerl (2014) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | Y | N | - |
| Fountoulakis and Moller (2014) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | N | N | - |
| Baldessarini (2014) | N-exp | N | N | Other | 9) | Psych | All | Drug | All | N | N | BJA Found; McLean PDRF; CPA |
| Prata *et al.* (2014) | N-exp | N | N | Moderate ES | - | Psych | Psychosis | Drug | Antipsych | Y | N | NIH; MRC |
| Mathie *et al.* (2014) | Exp | Y | N | Relevant small ES | - | Gen | All | Drug | Homeopathy | Y | Y | Man HC; BHA |
| Honyashiki *et al.* (2014) | Exp | Y | N | Relevant small ES | - | Psych | Affective | Psy | CBT | Y | N | MHLW Japan |
| Pingani *et al.* (2014) | N-exp | N | N | Large ES | - | Psych | All | Tx | All | N | N | - |
| Hampton *et al.* (2014) | Exp | N | N | Large ES | - | Psych | All | Drug | All | N | N | - |
| Wallace *et al.* (2014) | Exp | N | N | Other | 10) | Both | All | Edu | All | N | N | - |
| Huhn *et al.* (2014) | Exp | Y | N | Psych=Gen | - | Psych | All | Drug | All | Y | N | - |
| Mulsant *et al.* (2014) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | Y | N | NIMH |
| Breitenstein *et al.* (2014) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | NR | N | - |
| Schumann *et al.* (2014) | N-exp | N | N | Psych=Gen | - | Psych | All | Drug | All | Y | N | EU-FP7 |
| Enache-Tonoiu (2013) | N-exp | Y | N | Psych=Gen | - | Psych | All | Drug | All | NR | N | - |
| Maj (2013) | N-exp | Y | N | Psych=Gen | - | Psych | Psychosis | Drug | Antipsych | NR | N | - |
| Rickels and Robinson (2013) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | N | N | - |
| White *et al.* (2013) | Exp | Y | N | Psych=Gen | - | Gen | CFS | Psy | CBT; Exercise | N | N | MRC |
| Messori *et al.* (2013) | Exp | N | N | Other | 8) | Gen | Leukemia | Surgery | Transplant; chemo | N | N | - |
| van den Brink *et al.* (2013) | Exp | Y | N | Psych=Gen | - | Psych | Addiction | Drug | Nalmefene | Y | Y | Lundbeck |
| Klein and Berger (2013) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | Y | N | ERC |
| Frances (2013) | N-exp | N | N | Psych=Gen | - | Psych | All | Tx | All | N | N | - |
| Kane *et al.* (2013) | N-exp | N | N | Psych=Gen | - | Psych | Psychosis | Drug | Antipsych | Y | N | - |
| Elia *et al.* (2013) | N-exp | N | N | Large effect | - | Psych | ADHD | Drug | MPH | NR | N | - |
| Bauer *et al.* (2013) | N-exp | N | N | Other | 11) | Psych | Affective | Drug | Antidepr | Y | N |  |
| Fadda *et al.* (2013) | Exp | N | N | Other | 8) | Gen | Severely ill | Nutrition | Parent glut suppl | N | N | - |
| Reid (2013) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | Y | N | - |
| Casey (2013) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | N | N | - |
| Leventhal (2013) | N-expt | N | N | Psych=Gen | - | Psych | All | Drug | All | NR | N | \_ |
| Paris (2013) | N-exp | N | N | Psych=Gen | - | Psych | All | Drug | All | NR | N | - |
| Jones *et al.* (2013) | Exp | N | N | Large ES | - | Psych | All | Drug | All | NR | N | - |
| Everett *et al.* (2013) | N-exp | N | N | Other | 12) | Gen | All | Drug | All | Y | N | - |
| Leweke *et al.* (2012) | N-exp | N | N | Psych=Gen | - | Psych | Psychosis | Drug | Antipsych | NR | N | - |
| Haddad (2012) | N-exp | N | N | Psych=Gen | - | Psych | All | Drug | All | Y | N | - |
| Mugerwa and Holden (2012) | N-exp | Y | N | Relevant small ES | - | Gen | All | Psy | Expressive writing | NR | N | - |
| Reinhold *et al.* (2012) | N-exp | N | N | Other | 13) | Psych | Affective | Drug | Vilazodone | N | N | - |
| Leucht *et al.* (2012) | N-exp | N | N | Other | 8) | Psych | Psychosis | Drug | Antipsych | Y | N | - |
| Lawrence *et al.* (2012) | Exp | N | N | Psych=Gen | - | Psych | All | Drug | All | N | N | NINR |
| McGrath (2012) | N-exp | Y | N | Psych=Gen | - | Psych | All | Tx | All | NR | N | - |
| Stringaris (2012) | N-exp | Y | N | Psych=Gen | - | Psych | All | Tx | All | N | N | - |
| van Os and Howes (2012) | N-exp | N | N | Psych=Gen | - | Psych | Psychosis | Drug | Antipsych | Y | N | - |
| Kaplan (2012) | N-exp | Y | N | Psych=Gen | - | Psych | Affective | Drug | Antidepr | NR | N | - |
| Seemuller *et al.* (2012) | N-exp | Y | Y | Psych=Gen | - | Psych | All | Drug | All | Y | N | - |
| Johnsen and Kroken (2012) | N-exp | Y | N | Moderate ES | - | Psych | Psychosis | Drug | Antipsych | Y | N | - |

*Note.*

Abbreviations. Acad Finland, Academy of Finland; ADHD, Attention-Deficit and Hyperactivity Disorder; Antidepr, antidepressant; Antipsych, Antipsychotic; BAP, British Association for Psychopharmacology; BBRF, Brain and Behavior Research Fund; BHA, British Homeopathic Association; BH Found, Bertil Hållsten’s Foundation; BJA Found, Bruce J Anderson Foundation; CBASP, Cognitive Behavioral Analysis System of Psychotherapy; CBT, Cognitive Behavior Therapy; CCIR, Centre for Clinical Intervention Research; CFS, Chronic Fatigue Syndrome; Chemo, Chemotherapy; CPA, Canadian Psychiatric Association; COI, conflict of interest; Cond, Condition; Dexamph, Dexamphetamine; Edu, Educational; ERC, European Research Council; ES, effect size; EU, European Union; Exp, experimental; Found, Foundation; Gen, general medicine; Maltreat, Maltreatment; Man HC, Manchester Homeopathic Clinic; McLean PDRF, McLean Private Donors Research Fund; MI, Myocardial Infarction; MHLW, Ministry of Health, Labour and Welfare; MPH, Methylphenidate; MRC, Medical Research Council; N, no; NIH, National Institutes of Health; NIMH, National Institutes of Mental Health; NINR, National Institute of Nursing Research; NOHRD, Netherlands Organisation for Health Research and Development; Non-exp, non-experimental; Parent glut suppl, Parenteral glutamine supplementation; PDT, Psychodynamic therapy; Psy, psychological treatment; Psych, Psychiatry PTSD, Post-traumatic Stress Disorder; RGC, Research Grants Council; rTMS, Repetitive Transcranial Magnetic Stimulation; SBF, Swedish Brain Foundation; SJ Found, Sigrid Juselius Foundation; SMRC, Swedish Medical Research Council, S Found, Söderberg’s Foundation; SSRIs, Selective Serotonin Reuptake Inhibitors; SUH, Sahlgrenska University Hospital; Th, therapy; Treat, treatment; Tx, treatments (at least two different treatments from different categories); VA, Department of Veteran Affairs; WHO, World Health Organization; Y, yes

**a Point made:** Psych=Gen, the notion that treatment effectiveness in psychiatry closely resembles that in general medicine; Gen=Psych, the notion that treatment effectiveness in general medicine closely resembles that in psychiatry; Large ES, the notion that treatments have large effects; Moderate ES, the notion that treatments have moderate effects; Small ES, the notion that treatments have small effects; Relevant small ES, discussion of small effects not covered by the previous categories, such as a small effect claimed by comparison with the target paper, described as relevant but without making the parallel with general medicine; Other, other point when none of the previous categories applied.

**b Point (if other):**

1) An effective intervention is not equally effective for everyone in the population

2) Use of the same method as target paper

3) Psychotropic drugs are effective

4) Examples of effect sizes in general medicine

5) ES higher in long-term studies

6) Increase in placebo response

7) Medication cessation and relapse risk

8) Earlier trials show larger effects

9) Psychotropic drugs have favorable effects

10) Put different interventions into perspective

11) Drug placebo difference for antidepressant

12) Efficacy only achieved in subgroups

13) Uniformative comparative effectiveness

**References for included records**

**Adli, M. & Hegerl, U.** (2014). Do we underestimate the benefits of antidepressants? *Lancet* **383**, 1361-2.

**Aleman, A., Slotema, C. W. & Sommer, I. E.** (2014). rTMS deserves a fair chance as a novel treatment for depression. *Acta Psychiatr Scand* **130**, 324-5.

**Aubin, H. J. & Luquiens, A.** (2015). Feeding Two Birds with One Scone: The Case of Varenicline. *Alcohol Clin Exp Res* **39**, 2299-301.

**Aubin, H. J., Reimer, J., Nutt, D. J., Bladstrom, A., Torup, L., Francois, C. & Chick, J.** (2015). Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. *Eur Addict Res* **21**, 160-8.

**Baldessarini, R. J.** (2014). The impact of psychopharmacology on contemporary psychiatry. *Can J Psychiatry* **59**, 401-5.

**Banaschewski, T., Buitelaar, J., Chui, C. S., Coghill, D., Cortese, S., Simonoff, E. & Wong, I. C.** (2016). Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater. *Evid Based Ment Health* **19**, 97-99.

**Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J. & Moller, H. J.** (2013). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry* **14**, 334-85.

**Bhugra, D., Ventriglio, A., Kuzman, M. R., Ikkos, G., Hermans, M. H., Falkai, P., Fiorillo, A., Musalek, M., Hoschl, C., Dales, J., Beezhold, J., Rossler, W., Racetovic, G. & Gaebel, W.** (2015). EPA guidance on the role and responsibilities of psychiatrists. *Eur Psychiatry* **30**, 417-22.

**Biagianti, B., Fisher, M., Neilands, T. B., Loewy, R. & Vinogradov, S.** (2016). Engagement with the auditory processing system during targeted auditory cognitive training mediates changes in cognitive outcomes in individuals with schizophrenia. *Neuropsychology* **30**, 998-1008.

**Bisson, J. I., Cosgrove, S., Lewis, C. & Robert, N. P.** (2015). Post-traumatic stress disorder. *Bmj* **351**, h6161.

**Breitenstein, B., Scheuer, S. & Holsboer, F.** (2014). Are there meaningful biomarkers of treatment response for depression? *Drug Discov Today* **19**, 539-61.

**Bressington, D. & White, J.** (2015). Recovery from psychosis: physical health, antipsychotic medication and the daily dilemmas for mental health nurses. *J Psychiatr Ment Health Nurs* **22**, 549-57.

**Bschor, T. & Kilarski, L. L.** (2016). Are antidepressants effective? A debate on their efficacy for the treatment of major depression in adults. *Expert Rev Neurother* **16**, 367-74.

**Casey, D. A.** (2013). Do antidepressant medications work? *P and T* **38**, 162-163.

**Chan, M. H., Leung, P. W., Ho, T. P., Hung, S. F., Lee, C. C., Tang, C. P., Cheung, K. C., Ching, F. Y., Chan, F. H., Chen, L. H., Garcia-Barcelo, M. & Sham, P. C.** (2017). Are psychiatric comorbidities and associated cognitive functions related to treatment response to methylphenidate in boys with attention-deficit/hyperactivity disorder? *Neuropsychiatr Dis Treat* **13**, 1071-1080.

**Cleare, A., Pariante, C. M., Young, A. H., Anderson, I. M., Christmas, D., Cowen, P. J., Dickens, C., Ferrier, I. N., Geddes, J., Gilbody, S., Haddad, P. M., Katona, C., Lewis, G., Malizia, A., McAllister-Williams, R. H., Ramchandani, P., Scott, J., Taylor, D. & Uher, R.** (2015). Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. *J Psychopharmacol* **29**, 459-525.

**Connolly, J. J., Glessner, J. T., Elia, J. & Hakonarson, H.** (2015). ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder. *Ther Innov Regul Sci* **49**, 632-642.

**Correll, C. U. & Carbon, M.** (2014). Efficacy of pharmacologic and psychotherapeutic interventions in psychiatry: to talk or to prescribe: is that the question? *JAMA Psychiatry* **71**, 624-6.

**Cortese, S., D'Acunto, G., Konofal, E., Masi, G. & Vitiello, B.** (2017). New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability. *CNS Drugs* **31**, 149-160.

**Craddock, N. & Mynors-Wallis, L.** (2014). Psychiatric diagnosis: impersonal, imperfect and important. *Br J Psychiatry* **204**, 93-5.

**Cuijpers, P.** (2016). The future of psychotherapy research: stop the waste and focus on issues that matter. *Epidemiol Psychiatr Sci* **25**, 291-4.

**Cuijpers, P., Huibers, M. J. & Furukawa, T. A.** (2017). The Need for Research on Treatments of Chronic Depression. *JAMA Psychiatry* **74**, 242-243.

**Davey, C. G. & Chanen, A. M.** (2016). The unfulfilled promise of the antidepressant medications. *Med J Aust* **204**, 348-50.

**De Las Cuevas, C. & Penate, W.** (2015). Explaining pharmacophobia and pharmacophilia in psychiatric patients: relationship with treatment adherence. *Hum Psychopharmacol* **30**, 377-83.

**de Vries, Y. A., de Jonge, P., van den Heuvel, E., Turner, E. H. & Roest, A. M.** (2016). Influence of baseline severity on antidepressant efficacy for anxiety disorders: meta-analysis and meta-regression. *Br J Psychiatry* **208**, 515-21.

**DeRubeis, R. J., Cohen, Z. D., Forand, N. R., Fournier, J. C., Gelfand, L. A. & Lorenzo-Luaces, L.** (2014). The Personalized Advantage Index: translating research on prediction into individualized treatment recommendations. A demonstration. *PLoS One* **9**, e83875.

**Dold, M., Aigner, M., Lanzenberger, R. & Kasper, S.** (2015). Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. *Int J Neuropsychopharmacol* **18**.

**Dold, M. & Kasper, S.** (2015). Increasing placebo response in antipsychotic trials: a clinical perspective. *Evid Based Ment Health* **18**, 77-9.

**Elia, J., Kingsley, R., Lam, C., Takeda, T., de Berardinis, R., Laracy, S., Sackett, J., Tang, S. C., Schardt, M., Nivus, K., Hakonarson, H. & Algon, S.** (2013). Pharmacological treatment and prognosis of ADHD. In *ADHD: Clinical Management of Attention Deficit Hyperactivity Disorder*, pp. 73-102.

**Enache-Tonoiu, A.** (2013). Psychiatry and psychotherapy: A troubled relationship. *Europe's Journal of Psychology* **9**, 664-670.

**Everett, J. R., Loo, R. L. & Pullen, F. S.** (2013). Pharmacometabonomics and personalized medicine. *Ann Clin Biochem* **50**, 523-45.

**Fabbri, C., Crisafulli, C., Calabro, M., Spina, E. & Serretti, A.** (2016). Progress and prospects in pharmacogenetics of antidepressant drugs. *Expert Opin Drug Metab Toxicol* **12**, 1157-68.

**Fadda, V., Maratea, D., Trippoli, S. & Messori, A.** (2013). Temporal trend of short-term mortality in severely ill patients receiving parenteral glutamine supplementation. *Clin Nutr* **32**, 492-3.

**Florea, I., Danchenko, N., Brignone, M., Loft, H., Rive, B. & Abetz-Webb, L.** (2015). The effect of vortioxetine on health-related quality of life in patients with major depressive disorder. *Clin Ther* **37**, 2309-2323.e6.

**Fountoulakis, K. N. & Moller, H. J.** (2014). Are antidepressants clinically useful? Conclusion of a decade of debate. *World Psychiatry* **13**, 201-2.

**Fountoulakis, K. N., Samara, M. T. & Siamouli, M.** (2014). Burning issues in the meta-analysis of pharmaceutical trials for depression. *J Psychopharmacol* **28**, 106-17.

**Frances, A.** (2013). The new crisis of confidence in psychiatric diagnosis. *Ann Intern Med* **159**, 720.

**Frazer, A.** (2015). Neuropsychopharmacology: Reflections on 40 Volumes. *Neuropsychopharmacology* **40**, 2853-5.

**Goodwin, G. M., Haddad, P. M., Ferrier, I. N., Aronson, J. K., Barnes, T., Cipriani, A., Coghill, D. R., Fazel, S., Geddes, J. R., Grunze, H., Holmes, E. A., Howes, O., Hudson, S., Hunt, N., Jones, I., Macmillan, I. C., McAllister-Williams, H., Miklowitz, D. R., Morriss, R., Munafo, M., Paton, C., Saharkian, B. J., Saunders, K., Sinclair, J., Taylor, D., Vieta, E. & Young, A. H.** (2016). Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* **30**, 495-553.

**Gotzsche, P. C., Young, A. H. & Crace, J.** (2015). Does long term use of psychiatric drugs cause more harm than good? *Bmj* **350**, h2435.

**Haddad, P. M.** (2012). Ten principles of good psychiatric prescribing. *Medicine* **40**, 674-675.

**Hampton, L. M., Daubresse, M., Chang, H. Y., Alexander, G. C. & Budnitz, D. S.** (2014). Emergency department visits by adults for psychiatric medication adverse events. *JAMA Psychiatry* **71**, 1006-14.

**Hegerl, U. & Mergl, R.** (2014). Depression and suicidality in COPD: understandable reaction or independent disorders? *Eur Respir J* **44**, 734-43.

**Hieronymus, F., Nilsson, S. & Eriksson, E.** (2016). A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. *Transl Psychiatry* **6**, e834.

**Honyashiki, M., Furukawa, T. A., Noma, H., Tanaka, S., Chen, P., Ichikawa, K., Ono, M., Churchill, R., Hunot, V. & Caldwell, D. M.** (2014). Specificity of CBT for depression: A contribution from multiple treatments meta-analyses. *Cognitive Therapy and Research* **38**, 249-260.

**Hoskins, M., Pearce, J., Bethell, A., Dankova, L., Barbui, C., Tol, W. A., van Ommeren, M., de Jong, J., Seedat, S., Chen, H. & Bisson, J. I.** (2015). Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. *Br J Psychiatry* **206**, 93-100.

**Huber, D. & Klug, G.** (2015). Time in psychodynamic psychotherapy: Psychodynamic short-term versus long-term therapy. *Psychotherapeut* **60**, 94-101.

**Huhn, M., Tardy, M., Spineli, L. M., Kissling, W., Forstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M. & Leucht, S.** (2014). Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. *JAMA Psychiatry* **71**, 706-15.

**Hutton, P. & Taylor, P. J.** (2014). Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. *Psychol Med* **44**, 449-68.

**Jakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Moller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., Krogh, J., Ebert, S. E., Timm, A., Lindschou, J. & Gluud, C.** (2017). Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. *BMC Psychiatry* **17**, 58.

**Johnsen, E. & Kroken, R. A.** (2012). Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness. *Ther Adv Chronic Dis* **3**, 287-300.

**Jonas, W. B., Crawford, C., Colloca, L., Kaptchuk, T. J., Moseley, B., Miller, F. G., Kriston, L., Linde, K. & Meissner, K.** (2015). To what extent are surgery and invasive procedures effective beyond a placebo response? A systematic review with meta-analysis of randomised, sham controlled trials. *BMJ Open* **5**.

**Jones, N., Corrigan, P. W., James, D., Parker, J. & Larson, N.** (2013). Peer support, self-determination, and treatment engagement: a qualitative investigation. *Psychiatr Rehabil J* **36**, 209-14.

**Kane, J. M., Kishimoto, T. & Correll, C. U.** (2013). Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. *J Clin Epidemiol* **66**, S37-41.

**Kaplan, A.** (2012). On the efficacy of psychiatric drugs. *Psychiatric Times* **29**, 1+6-9.

**Kasper, S. & Dold, M.** (2015). Factors contributing to the increasing placebo response in antidepressant trials. *World Psychiatry* **14**, 304-6.

**Kaufman, J., Gelernter, J., Hudziak, J. J., Tyrka, A. R. & Coplan, J. D.** (2015). The Research Domain Criteria (RDoC) Project and Studies of Risk and Resilience in Maltreated Children. *J Am Acad Child Adolesc Psychiatry* **54**, 617-25.

**Kelly, B. D.** (2014). Rights of people with mental illness. *Lancet Psychiatry* **1**, e4.

**Klein, J. P. & Berger, T.** (2013). Internetbasierte psychologische behandlung bei depressionen. *Verhaltenstherapie* **23**, 149-159.

**Lally, J. & MacCabe, J. H.** (2015). Antipsychotic medication in schizophrenia: a review. *Br Med Bull* **114**, 169-79.

**Lawrence, R. E., Albert, K., Lidz, C. W. & Appelbaum, P. S.** (2012). Competing commitments in psychiatric research: an examination of psychiatric researchers' perspectives. *Int J Law Psychiatry* **35**, 380-6.

**Lawrie, S. M.** (2015). Patients need reliable facts and figures about antipsychotics. *Advances in Psychiatric Treatment* **21**, 85-87.

**Lehr, D., Heber, E., Sieland, B., Hillert, A., Funk, B. & Ebert, D. D.** (2016). Occupational eMental Health and teachers’ health: A meta-analytic review on the efficacy of internet-based intervention for promoting mental health in teachers. *Pravention und Gesundheitsforderung* **11**, 182-192.

**Leucht, S. & Davis, J. M.** (2017). Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. *Lancet* **389**, 1077-1078.

**Leucht, S., Helfer, B., Gartlehner, G. & Davis, J. M.** (2015). How effective are common medications: a perspective based on meta-analyses of major drugs. *BMC Med* **13**, 253.

**Leucht, S., Tardy, M. & Davis, J.** (2012). Authors' reply. *The Lancet* **380**, 1056.

**Leventhal, B. L.** (2013). Complementary and alternative medicine: Not many compliments but lots of alternatives. *Journal of Child and Adolescent Psychopharmacology* **23**, 54-56.

**Leweke, F. M., Odorfer, T. M. & Bumb, J. M.** (2012). Medical needs in the treatment of psychotic disorders. *Handb Exp Pharmacol*, 165-85.

**Liersch-Sumskis, S., Moxham, L. & Curtis, J.** (2015). Choosing to use compared to taking medication: the meaning of medication as described by people who experience schizophrenia. *Perspect Psychiatr Care* **51**, 114-20.

**Luderer, M., Bumb, J. M. & Sobanski, E.** (2016). Pharmacotherapy of adult ADHD. *Psychopharmakotherapie* **23**, 141-150.

**Maia, C. R., Stella, S. F., Mattos, P., Polanczyk, G. V., Polanczyk, C. A. & Rohde, L. A.** (2015). The Brazilian policy of withholding treatment for ADHD is probably increasing health and social costs. *Rev Bras Psiquiatr* **37**, 67-70.

**Maj, M.** (2013). Adherence to psychiatric treatments and the public image of psychiatry. *World Psychiatry* **12**, 185-6.

**Maj, M.** (2014). Technical and non-technical aspects of psychiatric care: the need for a balanced view. *World Psychiatry* **13**, 209-10.

**Mann, K., Torup, L., Sorensen, P., Gual, A., Swift, R., Walker, B. & van den Brink, W.** (2016). Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. *Eur Neuropsychopharmacol* **26**, 1941-1949.

**Mathie, R. T., Lloyd, S. M., Legg, L. A., Clausen, J., Moss, S., Davidson, J. R. & Ford, I.** (2014). Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis. *Syst Rev* **3**, 142.

**McGrath, J. J.** (2012). The early intervention debate provides a distraction from another 'unspeakable truth'. *Aust N Z J Psychiatry* **46**, 681-2.

**McIntyre, R. S., Harrison, J., Loft, H., Jacobson, W. & Olsen, C. K.** (2016). The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. *International Journal of Neuropsychopharmacology* **19**, pyw055.

**Messori, A., Fadda, V., Maratea, D. & Trippoli, S.** (2013). Acute lymphoblastic leukemia in first complete remission: temporal trend of outcomes in studies comparing allogeneic transplant with autologous transplant or chemotherapy. *Ann Hematol* **92**, 1221-8.

**Messori, A., Fadda, V., Maratea, D. & Trippoli, S.** (2014). Comparing benefits expected in the design of randomized trials with the results of mature meta-analysis: an analysis on aspiration thrombectomy in acute myocardial infarction. *Int J Cardiol* **176**, 1417-9.

**Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A. & Ogren, S. O.** (2015a). 60 years of advances in neuropsychopharmacology for improving brain health, renewed hope for progress. *Eur Neuropsychopharmacol* **25**, 591-8.

**Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A. & Ove Ogren, S.** (2015b). Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. *Eur Neuropsychopharmacol* **25**, 599-656.

**Moller-Leimkuhler, A. M., Moller, H. J., Maier, W., Gaebel, W. & Falkai, P.** (2016). EPA guidance on improving the image of psychiatry. *Eur Arch Psychiatry Clin Neurosci* **266**, 139-54.

**Moritz, S., Kolbeck, K. & Andreou, C.** (2016a). Antipsychotics decrease response confidence. *J Psychopharmacol* **30**, 831-3.

**Moritz, S., Woodward, T. S. & Balzan, R.** (2016b). Is metacognitive training for psychosis effective? *Expert Rev Neurother* **16**, 105-7.

**Mugerwa, S. & Holden, J. D.** (2012). Writing therapy: a new tool for general practice? *Br J Gen Pract* **62**, 661-3.

**Mulsant, B. H.** (2014). Is there a role for antidepressant and antipsychotic pharmacogenetics in clinical practice in 2014? *Can J Psychiatry* **59**, 59-61.

**Mulsant, B. H., Blumberger, D. M., Ismail, Z., Rabheru, K. & Rapoport, M. J.** (2014). A systematic approach to pharmacotherapy for geriatric major depression. *Clin Geriatr Med* **30**, 517-34.

**Naudet, F., Boussageon, R., Palpacuer, C., Gallet, L., Reymann, J. M. & Falissard, B.** (2015). Understanding the Antidepressant Debate in the Treatment of Major Depressive Disorder. *Therapie* **70**, 321-7.

**Nuijten, M., Blanken, P., van de Wetering, B., Nuijen, B., van den Brink, W. & Hendriks, V. M.** (2016). Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. *Lancet* **387**, 2226-34.

**Nutt, D. J., Goodwin, G. M., Bhugra, D., Fazel, S. & Lawrie, S.** (2014). Attacks on antidepressants: signs of deep-seated stigma? *Lancet Psychiatry* **1**, 102-4.

**O'Carroll, R. E.** (2014). Health psychology interventions. *Br J Health Psychol* **19**, 235-9.

**Oldham, M. A. & Ciraulo, D. A.** (2014). Bright light therapy for depression: a review of its effects on chronobiology and the autonomic nervous system. *Chronobiol Int* **31**, 305-19.

**Paris, J.** (2013). The ideology behind DSM-5. In *Making the DSM-5: Concepts and Controversies*, pp. 39-44.

**Pingani, L., Luciano, M., Sampogna, G., De Rosa, C., Pinna, F., Volpe, U., Del Vecchio, V. & Fiorillo, A.** (2014). The crisis in psychiatry: a public health perspective. *Int Rev Psychiatry* **26**, 530-4.

**Prata, D., Mechelli, A. & Kapur, S.** (2014). Clinically meaningful biomarkers for psychosis: a systematic and quantitative review. *Neurosci Biobehav Rev* **45**, 134-41.

**Reid, I. C.** (2013). Are antidepressants overprescribed? No. *Bmj* **346**, f190.

**Reinhold, J. A., Mandos, L. A., Lohoff, F. W. & Rickels, K.** (2012). Evidence for the use of vilazodone in the treatment of major depressive disorder. *Expert Opin Pharmacother* **13**, 2215-24.

**Rickels, K. & Robinson, D. S.** (2013). A Déjà Vu phenomenon in psychiatry. *Journal of Clinical Psychopharmacology* **33**, 591-592.

**Sayer, N. A., Noorbaloochi, S., Frazier, P. A., Pennebaker, J. W., Orazem, R. J., Schnurr, P. P., Murdoch, M., Carlson, K. F., Gravely, A. & Litz, B. T.** (2015). Randomized Controlled Trial of Online Expressive Writing to Address Readjustment Difficulties Among U.S. Afghanistan and Iraq War Veterans. *J Trauma Stress* **28**, 381-90.

**Schumann, G., Binder, E. B., Holte, A., de Kloet, E. R., Oedegaard, K. J., Robbins, T. W., Walker-Tilley, T. R., Bitter, I., Brown, V. J., Buitelaar, J., Ciccocioppo, R., Cools, R., Escera, C., Fleischhacker, W., Flor, H., Frith, C. D., Heinz, A., Johnsen, E., Kirschbaum, C., Klingberg, T., Lesch, K. P., Lewis, S., Maier, W., Mann, K., Martinot, J. L., Meyer-Lindenberg, A., Muller, C. P., Muller, W. E., Nutt, D. J., Persico, A., Perugi, G., Pessiglione, M., Preuss, U. W., Roiser, J. P., Rossini, P. M., Rybakowski, J. K., Sandi, C., Stephan, K. E., Undurraga, J., Vieta, E., van der Wee, N., Wykes, T., Haro, J. M. & Wittchen, H. U.** (2014). Stratified medicine for mental disorders. *Eur Neuropsychopharmacol* **24**, 5-50.

**Seemuller, F., Moller, H. J., Dittmann, S. & Musil, R.** (2012). Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication? *BMC Med* **10**, 17.

**Sinclair, J. M., Chambers, S. E., Shiles, C. J. & Baldwin, D. S.** (2016). Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. *Drug Saf* **39**, 627-45.

**Sommer, I. E. & Kahn, R. S.** (2014). Psychosis susceptibility syndrome: an alternative name for schizophrenia. *Lancet Psychiatry* **1**, 111.

**Stein, D. J.** (2015). Antidepressant-placebo differences: is the glass half full or half empty? *World Psychiatry* **14**, 257-8.

**Stringaris, A.** (2012). In this issue/abstract thinking: treatment response in psychiatry. *J Am Acad Child Adolesc Psychiatry* **51**, 561-2.

**Tajika, A., Ogawa, Y., Takeshima, N., Hayasaka, Y. & Furukawa, T. A.** (2015). Replication and contradiction of highly cited research papers in psychiatry: 10-year follow-up. *Br J Psychiatry* **207**, 357-62.

**Tansella, M., Thornicroft, G. & Lempp, H.** (2014). Lessons from community mental health to drive implementation in health care systems for people with long-term conditions. *Int J Environ Res Public Health* **11**, 4714-28.

**Taylor, D., Sparshatt, A., Varma, S. & Olofinjana, O.** (2014). Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. *Bmj* **348**, g1888.

**van den Brink, W., Aubin, H. J., Bladstrom, A., Torup, L., Gual, A. & Mann, K.** (2013). Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. *Alcohol Alcohol* **48**, 570-8.

**van den Brink, W., Mann, K., Gual, A. & Aubin, H. J.** (2014). Wim van den Brink and colleagues reply to Des Spence and Alain Braillon. *Bmj* **348**, g2605.

**van Os, J. & Howes, O. D.** (2012). Antipsychotic drugs for prevention of relapse. *Lancet* **379**, 2030-1.

**Veijola, J., Guo, J. Y., Moilanen, J. S., Jaaskelainen, E., Miettunen, J., Kyllonen, M., Haapea, M., Huhtaniska, S., Alaraisanen, A., Maki, P., Kiviniemi, V., Nikkinen, J., Starck, T., Remes, J. J., Tanskanen, P., Tervonen, O., Wink, A. M., Kehagia, A., Suckling, J., Kobayashi, H., Barnett, J. H., Barnes, A., Koponen, H. J., Jones, P. B., Isohanni, M. & Murray, G. K.** (2014). Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. *PLoS One* **9**, e101689.

**Wallace, J., Byrne, C. & Clarke, M.** (2014). Improving the uptake of systematic reviews: a systematic review of intervention effectiveness and relevance. *BMJ Open* **4**, e005834.

**Waszczuk, M. A., Li, X., Bromet, E. J., Gonzalez, A., Zvolensky, M. J., Ruggero, C., Luft, B. J. & Kotov, R.** (2017). Pathway from PTSD to respiratory health: Longitudinal evidence from a psychosocial intervention. *Health Psychol* **36**, 429-437.

**White, P. D., Goldsmith, K., Johnson, A. L., Chalder, T. & Sharpe, M.** (2013). Recovery from chronic fatigue syndrome after treatments given in the PACE trial. *Psychol Med* **43**, 2227-35.